ArticleQuantitative imaging in medicine and surgery2026
Deep medullar veins: predictors of clinical progression in Alzheimer's disease.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Explainable Machine Learning Reveals Time-Dependent Cognitive Risk in Minor Neurocognitive Disorder: Implications for Health Promotion and Early Risk Stratification.Biomedicines · 2026Article
- Deep medullary veins score is associated with idiopathic normal pressure hydrocephalus in patients with arteriolosclerotic cerebral small vessel disease.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early detection of Alzheimer's disease (AD) remains challenging due to limited biomarkers. This retrospective longitudinal study evaluated whether alterations in the deep medullary veins (DMVs) predict cognitive decline. Methods: We analyzed 170 participants from the Open Access Series of Imaging Studies-3 (OASIS-3) database [95 cognitive normal (CN), 36 mild cognitive impairment (MCI), and 39 AD]. DMVs were scored on susceptibility-weighted imaging (SWI). Cox proportional hazard models assessed the association between DMVs and longitudinal cognitive decline. Mediation analysis tested whether amyloid-β (Aβ) partially mediates the effect of DMVs on cognition. Results: DMVs scores increased across groups {7 [6, 8] in CN, 13 [8.25, 15] in MCI, and 14 [13, 15] in AD; P<0.001}. DMVs score correlated with age (r=0.371, P<0.001), Mini-Mental State Examination (MMSE) (r=-0.494, P<0.001), cortical volume (r=-0.371, P<0.001), and Aβ burden (r=0.498, P<0.001). A higher DMVs score was associated with an increased risk of cognitive progression in AD [hazard ratio (HR) =1.13, 95% confidence interval (CI): 1.02-1.24, P=0.014], demonstrating good classification performance [area under the curve (AUC) =0.800, P<0.001]. Mediation analysis showed Aβ burden partially mediated the DMVs effect on MMSE (indirect effect β=-0.154, 95% CI: -0.337 to -0.017). Conclusions: DMVs alterations increase with AD severity, correlate with Aβ deposition, and predict cognitive decline, suggesting DMVs score as a promising imaging biomarker for early identification of individuals at risk of AD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.